DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 11:00:00 03/07/2024 pm IST			5-day change	1st Jan Change
2.89 ^USD	+3.21%		-2.36%	+1.76%

01/07	DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding	CI
27/06	Transcript : DiaMedica Therapeutics Inc. - Special Call

DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding

July 01, 2024

On July 1, 2024, DiaMedica Therapeutics Inc., closed the transaction. The company received funding pursuant to exemption provided under Regulation D, The transaction included participation from 10 investors.

Latest news about DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding	01/07	CI
Transcript : DiaMedica Therapeutics Inc. - Special Call	27/06
DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia	26/06	CI
DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding	25/06	CI
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director	24/05	CI
Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	18/04	MT
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	18/04	CI
DiaMedica Therapeutics Inc. Announces Executive Changes	11/04	CI
DiaMedica Therapeutics Files $100 Million Mixed Shelf	22/03	MT
Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating	21/03	MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating	21/03	MT
Transcript : DiaMedica Therapeutics Inc., 2023 Earnings Call, Mar 20, 2024	20/03
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	23/01	MT
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22/01	CI
Transcript : DiaMedica Therapeutics Inc., Q3 2023 Earnings Call, Nov 14, 2023	14/11
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Top Premarket Gainers	25/23/25	MT
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer	12/23/12	CI
Diamedica Therapeutics Inc. Announces Management Changes	06/23/06	CI
Transcript : DiaMedica Therapeutics Inc., Q2 2023 Earnings Call, Aug 15, 2023	15/23/15
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
DiaMedica Therapeutics Inc. announced that it has received $37.4 million in funding	14/23/14	CI

Chart DiaMedica Therapeutics Inc.

Duration

Period

More charts

Company Profile

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Sector

Biotechnology & Medical Research

Calendar

29/07/2024 - Investor Meeting - Key Opinion Leader

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.89 USD

Average target price

7 USD

Spread / Average Target

+142.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DIAMEDICA THERAPEUTICS INC.	+1.76%	11Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	12TCr
REGENERON PHARMACEUTICALS, INC.	+16.60%	11TCr
ARGENX SE	+17.55%	2.62TCr
BIONTECH SE	-24.33%	1.9TCr
GENMAB A/S	-19.14%	1.57TCr
BEIGENE, LTD.	-17.95%	1.52TCr
WUXI APPTEC CO., LTD.	-46.81%	1.47TCr
SAREPTA THERAPEUTICS, INC.	+58.78%	1.46TCr
NEUROCRINE BIOSCIENCES, INC.	+4.91%	1.38TCr

Bio Therapeutic Drugs